Vincerx Pharma, Inc. Common Stock

Vincerx Pharma, Inc. is a clinical-stage biopharmaceutical company developing differentiated and novel therapies for cancer patients with unmet medical needs in the United States. Its VersAptx bioconjugation platform combines targeting, linker, and payload technologies to develop antibody-drug conjugates (ADCs) and small molecule drug conjugates (SMDCs), and includes CellTrapper technology to reduce payload cellular permeability. The company is developing VIP943, an ADC in a Phase 1 dose-escalation study for relapsed/refractory acute myeloid leukemia, higher-risk MDS, and B-cell acute lymphoblastic leukemia; VIP236, an SMDC in a Phase 1 dose-escalation study for advanced or metastatic solid tumors; and VIP924, an anti-CXCR5 ADC using the same effector chemistry in preclinical studies for B-cell malignancies. It collaborates with the National Institutes of Health on a Phase 1 dose-escalation study of enitociclib, a highly selective cyclin-dependent kinase 9 inhibitor. Formerly known as Vincera Pharma, Inc., it changed its name to Vincerx Pharma, Inc. in January 2021. Founded in 2019, the company is headquartered in San Mateo, California.